Assessing Clinical Outcomes, Quality Of Life, And Treatment Toxicities In Advanced-Stage Cancer Patients: A Focus On Tumour Response And Symptom Management

Article Sidebar

Pdf
Published: Dec 30, 2023
DOI: https://doi.org/10.53555/jrtdd.v6i10s(2).3885
Keywords:
Cancer, Quality of Life, Tumour Response, Treatment Toxicity, Symptom Management

Main Article Content

Dr Modepalli Pavan Kumar

Abstract

Cancer has been one of the health problems in the world with high-stage cancers having the worst prognosis and difficult treatment procedures. The reason behind this study was to measure clinical outcomes, quality of life (QoL) and treatment associated toxicity in a cohort of 60 patients receiving treatment on advanced stage cancer, mainly adenocarcinoma. The patients were largely males (58.3) with a median age of 62 years and had already received previous chemotherapy. The researchers assessed the tumour response based on RECIST which showed a response rate of 33.3% and 36.7% of patients had progressive disease. Control of the disease was done in 56.7% of the patients. Treatment-related toxicities were common (acnesiform rash 70%), diarrhoea (36.7%), and stomatitis (11.7%), Grade 1 being the most common in all cases. The overall QoL increased by a significant margin in all domains, with Global QoL 36.2 to 55.1 (p = 0.01) and physical functioning increasing by 47.31 to 65.07 (p = 0.01). There was also an improvement in symptom management and fatigue, loss of appetite, dyspnoea, and coughing were reduced significantly. Nonetheless, there was no significant improvement in haemoptysis (p = 0.21). The objective tumour responders were found to have a better QoL and functioning in physical, role and social domain than their non-responders. The findings emphasize the need to focus on clinical efficacy and symptom management as two critical aspects of cancer treatment to have the maximum patient outcomes. The paper highlights the importance of close attention to treatment-related toxicities and constant supportive care, particularly in late cancer conditions, to increase QoL and efficacy of treatment.

Article Details

How to Cite
Dr Modepalli Pavan Kumar. (2023). Assessing Clinical Outcomes, Quality Of Life, And Treatment Toxicities In Advanced-Stage Cancer Patients: A Focus On Tumour Response And Symptom Management. Journal for ReAttach Therapy and Developmental Diversities, 6(10s(2), 2438–2443. https://doi.org/10.53555/jrtdd.v6i10s(2).3885
Issue
Vol. 6 No. 10s(2) (2023)
Section
Articles
Author Biography

Dr Modepalli Pavan Kumar

Assistant Professor, Department of Dermatology, Sri Lakshmi Narayana Institute of Medical Sciences, Puducherry - 605502.

References

Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trails. BMJ. 1995;311:899–909.

Haura EB. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control. 2001;8:326–336.

Rowinsky EK. The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents. Drugs. 2000;60:1–14.

Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997;3:515–522.

Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, McIntosh J, Kurie J, Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53:2379–2385.

Cerny T, Barnes DM, Hasleton P, Barber PV, Healy K, Gullick W, Thatcher N. Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer. 1986;54:265–269.

Nakagawa K, Tamura T, Negoro S, Kudoh S, Yamamoto N, Yamamoto N, Takeda K, Swaisland H, Nakatani I, Hirose M, Dong RP, Fukuoka M. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 2003;14:922–930.

Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137–139.

Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa®) tablets. Oncologist. 2003;8:303–306.

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:2237–2246.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the EORTC Quality of Life Group . The EORTC QLQ-C30 Scoring Manual. 3. European Organization for Research and Treatment of Cancer, Brussels, Belgium; 2001.

Stephens RJ, Hopwood P, Girling DJ. Defining and analysing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer. 1999;79:538–544.

Langendijk JA, Aaronson NK, de Jong JM, ten Velde GP, Muller MJ, Lamers RJ, Slotman BJ, Wouters EF. Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol. 2001;19:2123–2133.

van Putten JW, Baas P, Codrington H, Kwa HB, Muller M, Aaronson N, Groen HJ. Activity of single-agent gemcitabine as second-line treatment after previous chemotherapy or radiotherapy in advanced non-small-cell lung cancer. Lung Cancer. 2001;33:289–298.

Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. pp. 2149–2158. 2003 Oct 22.

Forsythe B, Faulkner K. Safety and tolerability of gefitinib ('Iressa', ZD1839) in advanced NSCLC: overview of clinical experience. Poster presented at ERS 13th Annual Congress, Vienna, Austria, Poster no P327. September 27-October 1, 2003.

Herbst RS. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients. Semin Oncol. 2003;30:30–38.

Cella D. Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale. Semin Oncol. 2003;30:39–48.

Montazeri A, Gillis CR, McEwen J. Quality of life in patients with lung cancer: a review of literature from 1970 to 1995. Chest. 1998;113:467–481.

Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res. 2000;9:129–137.